Immunohistochemical analysis of the DNA methyltransferase 3b expression is associated with significant improvements in the discrimination of ulcerative colitis-associated neoplastic lesions

Surgery Today

Volumn 43, Issue 11, 2013, Pages 1275-1280

  Ueda, Hirofumi ^a,b   Tanaka, Hiroyuki ^a,c   Ichikawa, Kazuhito ^a   Itabashi, Michio ^d   Kameoka, Shingo ^d   Fujii, Shigehiko ^e   Saito, Natsuko ^a   Kimura, Ryusuke ^a   Shida, Yosuke ^a   Fujimori, Yukari ^a   Ohtake, Shinichirou ^a   Tomita, Shigeki ^a   Imura, Johji ^a   Yasuda, Yoshikazu ^c   Tanigawa, Nobuhiko ^b   Uchiyama, Kazuhisa ^b   Fujimori, Takahiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e KYOTO KATSURA HOSPITAL   (Japan)

Author keywords

DNA methyltransferase 3b; Dysplasia; New molecular marker; Ulcerative colitis

Indexed keywords

DNA METHYLTRANSFERASE 3B;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLORECTAL TUMOR; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EPITHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; MALE; NEOPLASM; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; ULCERATIVE COLITIS; ULCERATIVE COLITIS ASSOCIATED NEOPLASIA;

ADULT; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED;

EID: 84886085190     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-012-0456-6     Document Type: Article

References (23)

1. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228-33.
2. Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 1988;29:206-17.
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-35.
4. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140:1807-16.
5. Choi PM, Nugent FW, Schoetz DJ, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993;105:418-24.
6. Itzkowitz SH, Present DH. Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group: consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflammatory Bowel Dis. 2005;11:314-21.
7. Collins RH, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. N Engl J Med. 1987;316:1654-8.
8. Fujii S, Katsumata D, Fujimori T. Limits of diagnosis and molecular markers for early detection of ulcerative colitis-associated colorectal neoplasia. Digestion. 2008;77(suppl 1):2-12.
9. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931-68.
10. Naish SJ, Boenisch T, Farmilo AJ, Stead RH, editors. Handbook- immunochemical staining methods. Carpinteria: Dako; 1989.
11. Fujii S, Katake Y, Tanaka H. Increased expression of DNA methyltransferase-1 in non-neoplastic epithelium helps predict colorectal neoplasia risk in ulcerative colitis. Digestion. 2010;82:179-86.
12. Brentnall TA, Crispin DA, Rabinovitch PS, Hagitt RC, Rubin CE, Stevens AC, et al. Mutation in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107:369-78.
13. Holzmann K, Klump B, Borchard F, Hsieh CJ, Kühn A, Gaco V, et al. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colorectomy specimens with long-standing ulcerative colitis. Int J Cancer. 1998;76:1-6.
14. Sakuma K, Fujimori T, Hirabayashi K, Terano A. Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer. J Gastroenterol. 1999;34:189-94.
15. Wong NACS, Mayer NJ, MacKell S, Gilmour HM, Harrison DJ. Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia. Histopathology. 2000;37:108-14.
16. Fujii S, Fujimori T, Chiba T. Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia. J Exp Clin Cancer Res. 2003;22:107-15.
17. Fujii S, Fujimori T, Kawamata H, Takeda J, Kitajima K, Omotehara F, et al. Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. Gut. 2004;53:710-6.
18. Tanaka H, Fukui H, Fujii S, Sekikawa A, Yamagishi H, Ichikawa K, et al. Immunohistochemical analysis of REG Iα expression in ulcerative colitis-associated neoplastic lesions. Digestion. 2011;83:204-9.
19. Ibrahim AE, Arends MJ, Silva AL, Wyllie AH, Greger L, Ito Y, et al. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut. 2011;60:499-508.
20. Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, et al. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res. 2009;15:3663-71.
21. Qu Y, Mu G, Wu Y, Dai X, Zhou F, Xu X, et al. Overexpression of DNA methyltransferases 1, 3a, and 3b significantly correlates with retinoblastoma tumorigenesis. Am J Clin Pathol. 2010;134:826-34.
22. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416:552-6.
23. Beaulieu N, Morin S, Chute IC, Robert MF, Nquyen H, MacLeod AR. An essential role for DNA methyltransferase DNMT3B in cancer cell survival. J Biol Chem. 2002;277:28176-81.